Related Experiment Video
Updated: Jul 15, 2025
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats
Márta Sárközy1,2, Simon Watzinger3, Zsuzsanna Z A Kovács1,2
1MEDICS Research Group, Department of Biochemistry, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Insights
Recombinant human neuregulin-1β therapy improved kidney function and alleviated uremic cardiomyopathy in a preclinical model. These findings suggest potential benefits for chronic kidney disease patients.
Area of Science:
- Nephrology
- Cardiology
- Biomedical Science
Background:
- Chronic kidney disease (CKD) affects 10-12% of the global population.
- Uremic cardiomyopathy in CKD involves left ventricular hypertrophy, fibrosis, and diastolic dysfunction.
- Neuregulin-1β signaling dysregulation contributes to cardiac dysfunction in CKD.
Purpose of the Study:
- To investigate the therapeutic potential of recombinant human neuregulin-1β (rhNRG-1β) in a preclinical model of CKD.
- To assess the effects of rhNRG-1β on uremic cardiomyopathy and kidney dysfunction.
Main Methods:
- A 5/6 nephrectomy model was used to induce CKD in rodents.
- Systemic administration of rhNRG-1β for 10 days.
- Evaluation of cardiac and kidney function parameters.
Main Results:
- rhNRG-1β treatment alleviated the progression of uremic cardiomyopathy.
- rhNRG-1β treatment improved kidney dysfunction in the CKD model.
- Observed benefits in type 4 cardiorenal syndrome.
Conclusions:
- Systemic rhNRG-1β demonstrates significant preclinical efficacy in mitigating CKD-associated cardiac and kidney damage.
- Positive preclinical data support further clinical investigation of rhNRG-1β for CKD patients.
Abstract:
Chronic kidney disease is a global health problem affecting 10% to 12% of the population. Uremic cardiomyopathy is often characterized by left ventricular hypertrophy, fibrosis, and diastolic dysfunction. Dysregulation of neuregulin-1β signaling in the heart is a known contributor to heart failure. The systemically administered recombinant human neuregulin-1β for 10 days in our 5/6 nephrectomy-induced model of chronic kidney disease alleviated the progression of uremic cardiomyopathy and kidney dysfunction in type 4 cardiorenal syndrome. The currently presented positive preclinical data warrant clinical studies to confirm the beneficial effects of recombinant human neuregulin-1β in patients with chronic kidney disease.
